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There are conflicting views on the nature of subgroups A, and A2 of blood group A, 
One holds that the same determinants are present on either, but that there are fewer 
determinants on A2 than on A, erythrocytes. Soluble A2 and A, substances would thus 
have  the  same  kinds  of determinants,  but  in  different  numbers.  The  A1  and  A2 
transferases  are  different  enzymes,  but  the  A2  enzyme is  less  efficient  than  the  A, 
transferase, but it has the same specificity (1) in adding terminal N-acetyl-D-galactosa- 
minyl residues to precursor blood group H oligosaccharide side chains. Such a difference 
in enzymatic activity has been proposed to be responsible for the H activity of A2 cells 
(2). A population of those anti-A, antibodies which do not agglutinate A2 erythrocytes is 
known and has been prepared from the purified IgM fraction of anti-A sera by absorption 
with A2 erythrocytes, but not from the IgG fractions of the same sera (3). Such anti-A 
antibodies have been assumed (3) to have a  low affinity so that if they use only one of 
their  ten  valences  per  erythrocyte,  they  would  be  unable  to  hold  two  erythmcytes 
together. The anti-A, antibodies are hypothesized to agglutinate A, erythrocytes which 
have receptors that are more numerous and closer together,  so that each erythrocyte 
could be bound by two or more of the combining sites of each antibody molecule. 
The other concept, based predominantly on immunochemical studies with A1 and A2 
glycoproteins, favors a qualitative difference (4). Absorption with insolubilized polyleucyl 
A2 substance did not remove all of the anti-A, but left anti-A~; had all determinants been 
present on A2 as well as on A~ substances, no anti-A~ should have remained. 
Since several different determinants on soluble blood group A substances have been 
found  (5,  6,  7),  a  basis  for a  structural  difference between  A~  and  A2 exists.  All  A 
determinants have the structure 
~ucal 
2 
DGalNAcal--*3DGal 
but differ in that this trisaccharide may be linked /~1--.3 or B1~4 to vGlcNAc to give 
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FIG.  1.  (a) Structure  in blood group A glycoprotein proposed for A specificity; DGalNAc, 
substituted  al-*3 on the type 1 chain, is hypothesized to be Al-specific, and on the type 2 
chain, A2-specific. (b) Structure  in blood group A glycoprotein proposed for A2 specificity; 
the  chain  lacking  the  l~GalNAc is  HLeb-spocific. (c) Type  2 chain joined  ill-*6  to N- 
acetylgalactosamine,  compound JS R~Ms0.91 (14). 
what have been termed (8, 9, 10) type 1 and type 2 blood group A determinants (Fig.  1). 
A  second  LFUC linked  al--*4  or  al--*3  to  the  vGlcNAc also  gives  two  additional  A 
determinants, and antibodies specific for the mono- or difucosyl determinants have been 
recognized (11). In the intact blood group substance, these oligosaccharide type 1 and 
type 2 determinants are linked ill--*3 and ill--->6, respectively, to DGal. 
The type 2 H  determinant  may be  linked  ill--*6  to the  vGalNAc which had been 
cleaved from the  pelypeptide backbone  (Fig.  l c),  and by analogy to oligosaccharides 
isolated from blood group B substance (12, 13) it could have an additional DGalNAcal--*3, 832  IMMUNOCHEMICAL  STUDIES  ON  BLOOD  GROUPS 
linked to the subterminal DGal of the H determinant in Fig. 1 c (14), to give a second type 
2 A determinant.  If, as hypothesized (4), A1 substances have both type 1 and type 2 A 
determinants  (Fig.  I a) whereas A2 substances  lack the nonreducing  DGalNac linked 
al---)3 of the type 1 A determinant (Fig. 1 b), anti-A, would consist of antibodies specific 
for type 1 A determinants,  and it would not be removed by insoluble A2 substance, as 
was found. Moreover, the absence of the terminal ~:~alNAc~l--->3 on the type 1 chains 
would provide the many H  determinants found on A2 substances, and these should be 
type 1 H specific. 
The  distinction  between  A,  and  A2  is  further  complicated  by  the  inference  that 
erythrocytes  contain  only  type  2  chains  (15) from  experiments  in  which  an  HLe  b 
glycoprotein purified from O  erythrocytes by the procedure of Marchesi and Andrews 
(16) was radiolabeled with  [~4C]N-acetyl-D-galactosamine by an enzyme from group A 
human milk. After alkaline berohydride degradation (17), all of the label in the reduced 
oligosaccharides  was  subsequently  released  by  an  endo-B-galactosidase  (18) which 
specifically cleaves the ill--*4  link in 
LFucal 
2 
DGalNAcal--)3DGalB1---)4I~lcNAc or DGlc 
or 
DGal. 
Had type 1 chains been present and hod they been labeled, they would not have been 
split (18); no type 1 chain was found. However, it is well established that HLe  b specificity 
(19, 20) requires a second fucose on the type 1 chain, and that the N-acetyl-galactosami- 
nyl blood group A transferase does not act on difucosyl H determinants (21, 22). There is 
thus no reason to believe that the type 1 HLe  b determinants were labeled. 
A competitive binding assay is used in the present study to compare inhibition by A1 
and As blood group substances of binding of tritium-labeled blood group A substance by 
insolubilized lectin and antiserum.  Slopes of inhibition curves reflect the nature of the 
interaction of antigens with the combining sites of the antibodies. Structurally related or 
identical antigens should yield parallel inhibition lines, whereas structurally different 
ones  will  give  nonparallel  lines.  Slopes of curves  were  the  same  with  insolubilized 
Dolichos  biflorus,  a  lectin  which  precipitates  blood  group  A  substances  and  has  a 
specificity for terminal a-linked DGalNAc, and for the trisaccharide moiety 
LFucal 
2 
DGalNAc  al--~3DGal~  (23). 
With human anti-A,  differences in slope between A~  and As were found,  indicating a 
qualitative  difference  between  these  substances  themselves  and  the  population  of 
antibodies with which each reacts. 
The affinities of anti-A sera and anti-A s~ra absorbed on polyleucyl-A~ or polyleucyl- 
A  insolubilized blood group substances were analyzed by a  modified competition assay 
(24, 25). The slopes of the inhibition curves are proportional to the relative affinities of 
the  antibodies.  Anti-A~  antibodies  not  absorbed  on  pelyleucyl-A2 substance  retained 
their high affinity for labeled blood group A substance, whereas partial absorption of the 
same anti-A serum with polyleucyl blood group substances having A1 and As determi- 
nants  leil antibodies  of much lower affinity in  the  supernate.  This is in substantial 
disagreement with a key assumption of the hypothesis that the differences between A~ 
and A2 are only quantitative  (3) which requires that the anti-At  antibodies be of low 
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This evidence strongly favors a  structural difference in the A  determinants of water 
soluble A, and A2 glycoproteins with a distinct population of antibodies specific for each 
determinant, and thus raises the question of whether or not type 1 A determinants will 
not eventually be found on the blood group A  erythrocyte. 
Materials and Methods 
Blood group substance used in competitive binding assays (CBA)  1  was isolated from [3H]acetic 
anhydride-labeled hog mucin A + H (26, 27) by affinity chromatography on a Dolichos-Sepharose 
2B column. The absorbed, A-active material was eluted with vGalNAc as previously described 
(26, 27). Inhibiters used in CBA included human blood group A, substances MSM 10%, MSS 10% 
(28), and Cyst 9 from Dr. Harold Baer (29), and human blood group .%2 substance Cyst 14 phenol 
insoluble (4). Cyst 14 fucose eluate and Cyst 14 effluent are fractions from Cyst 14 phenol insoluble 
separated by affinity chromatography on Lotus-Sepharose  (30). An A2 substance prepared from 
human saliva W. G. phenol insoluble was also available (31). Hog blood group A substance, hog 
gastric mucin (HGM) GalNAc eluate was also used; it reacts like human A1 substances (30). 
Ethyl chloroformate insolubilized (32, 33) human anti-A serum Chris D2 (34) and D. biflorus 
(23) inselubilized on  cyanogen bromide-activated Sepharose  2B  (30, 35-37) were prepared  as 
described earlier (26). Whole anti-A serum was acidified by adding 1.0 M sodium acetate-acetic 
acid buffer, pH 4.6, to a final concentration of 0.20 M (pH 4.9-5.0).  Ethyl chloroformate (0.05 ml/ 
ml serum)  was added by drops with sufficient stirring to keep it in suspension.  An abundant 
precipitate formed within 15 min; stirring was stepped and the mixture was placed in a refrigerator 
for  16  h.  The  insoluble serum  was dispersed with  a  Kontes glass  homogenizer (Kontos  Co., 
Vineland, N. J.), centrifuged at 1,200g  at 4°C for 1 h, the precipitate washed once with cold 0.1% 
Na2CO3, and then repeatedly with 10 mM phosphate-buffered saline containing 0.1% NaN3 until 
the OD280 of  the washings was <0.02. The final pellet was stored at 4°C until needed. TheDolichos 
lectin was coupled to Sepharose 2B in the presence of 0.1 M vGalNAc to protect the sites. 
Sera were absorbed by passing samples of Chris D2 or dos D1  +  D2 (34) through columns of 
polyleucyl iusolubilized  blood  group  substance  (4). Two  5-ml  portions  were  passed  through 
individual columns of PL-Cyst 14 phenol insoluble (A2) and PL-Hog A (A1). The effluent sera from 
the PL-BGS columns were tested for their precipitating capacity by quantitative precipitin assay 
(38). Samples of Christ and Jos absorbed  in the previous study (4) on PL-Cyst  14 (A2), PL-Hog A 
(A1), and PL-McDon (A,) were available. 
Two types  of CBA were  performed.  One measured  competition for insolubilized Chris,  or 
Dolichos-Sepharose between labeled and unlabeled blood group substance; in the other, competi- 
tion for the labeled blood group substance between inselubilized Chris and soluble antibodies was 
assayed.  For the competition assay with unlabeled blood group substance, ----2,000 cpm of HGM 
GalNAc eluate were mixed with varying amounts of unlabeled blood group substance followed by 
an amount of insolubilized Chris or ofDolichos-Sepharose sufficient to bind 50-60% of the labeled 
material.  The tubes  were mixed by  rotation for  16  h  at  4°C. Separation  of bound  from free 
radioactivity and preparation of the samples for counting was as previously described  (26, 27). In 
the soluble antibody CBA, a constant amount of insolubilized Chris, sufficient to bind 50-60% of 
the labeled HGM GalNAc eluate, was mixed with varying amounts  (measured  in ng AbN/ml 
from a  quantitative precipitin curve with MSM  10%) of antiserum  containing the competing 
antibodies. A constant amount, ~ 2,000 cpm of labeled blood group substance,  was then added. 
The tubes were rotated in the cold for 16 h  and processed as above. The total volume in both 
assays was 350 ~l. 
In both assays, the data were expressed graphically as the percent of inhibition (of binding of 
labeled antigen) versus nanograms of blood group substance, or of AbN added.  The formula used 
to compute percent of inhibition was: 
1  total cpm added_ -_ cpm in supernate_ with inhibiter  ~  100. 
total cpm added -  cpm in supernate without inhibitor /  × 
The slopes of the lines in the linear portion of the sigmoid plot expressed as the change in percent 
of inhibition per one log unit, are computed as the difference in percent of inhibition for two points 
~Abbreviations  used  in  this  paper:  CBA,  competitive binding  assay;  HGM,  hog  gastric 
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one log unit apart on the linear part of the graph.  All determinations  were set up in duplicate, 
and analyses did not generally  differ  by more than ±5%. Competitive binding  data in the figures 
give combined  results of three experiments  with each substance. 
Binding  data presented  in this manner will take the form  ofa sigmoid  curve  for a uniform  set of 
sites. We will be discussing  the apparent slopes of the lines in the linear portion of  the curves and 
the concentration  (blood  group substance or antibody  added) at half  saturation. The concentration 
at half saturation reflects the apparent bir~ding constant. The apparent slope gives an indication 
of interactions or heterogeneity  or beth. 
Results 
CBAs of  A 1  and A 2  Blood Group Substances with Insolubilized Antiserum and 
Lectin.  Fig.  2 a  is the CBA with Dolichos-Sepharose  and various A1  and A2 
substances. A1 and A2 substances differ in the amount required to inhibit 50% 
binding; 11-12 times more A2 than A1 substance by weight is needed, reflecting 
a  quantitative  difference between  them  with  respect  to  the  number  of A 
determinants of the structure 
LFucal 
2 
DGalNAc  al-*3DGal--*. 
The two human A1 substances and the HGM GalNAc eluate fall on the same 
line and therefore they have similar numbers of determinants. The various A2 
substances, WG phenol insoluble, the Cyst 14 fucose eluato, and unfractionated 
Cyst 14, also have the same number of determinants, but 1/11 as many as the 
A~ substances, and they fall on another line. The slopes of  the lines are similar, 
indicating a similar binding affinity  for the Doliehos site of the determinants in 
both A~ and A2 substances. 
Fig. 2 b  is a  CBA using the same blood group substances with insolubilized 
human anti-A Chris.  The A~  substances are 7- to  10-fold better inhibitors of 
binding than are the A2 substances, as reflected by the amounts needed for 50% 
inhibition. In contrast to the findings with Dolichos,  individual A~ substances 
vary in inhibiting power per  unit of weight,  and hence in their numbers of 
determinants. Quantitative precipitin data (4, 30) support these findings; MSM 
10%,  the  best  inhibitor,  with  140  ng for 50%  inhibition,  requires  1.6  /~g of 
substance to precipitate 50% of  the Chris N which it precipitated at equivalence, 
whereas the HGM GalNAc eluate, 190 ng for 50% inhibition, or 25% less active 
than MSM 10%, needs 2.0/~g for 50% precipitation. There are no data for MSS 
10%. Cyst 14 phenol insoluble, WG phenol insoluble, and Cyst 14 fucose eluate 
are all equal within experimental error. Cyst 14 effluent is -  2.5 times poorer in 
CBA than are the other A2 substances, in agreement with the finding that more 
than twice as much Cyst 14 effluent, as Cyst 14 phenol insoluble, is needed for 
50% precipitation, 5 and 2 ~tg, respectively. 
As in the case of Dolichos  assay, these differences between A~  and A2 are 
consistent with a larger number of receptors on A~ substances than on A2. The 
slopes  of the  A~  and  A2  lines  differ; e.g.,  the  ratio  of amount of A~  to  A2 
substance required to inhibit a given percent of  binding decreases as the percent 
of  inhibition  increases,  indicating  that  A1  substance  competes  relatively 
stronger with the labeled HGM GalNAc eluate for antibody combining sites EDWARD C.  KISAILUS  AND  ELVIN  A.  KABAT  835 
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FIG.  2.  Competitive binding assays of various A, and A2 blood group substances with (a) 
Dolichos-Sepharose 2B and (b) insolubilized human anti-A Chris and [3H]HGM GalNAc 
eluate. The quantity of antigen giving 50% inhibition of binding is indicated by an arrow 
(semilog plot). A,: I, MSM 10%; [~, MSS 10%; x, HogA GalNAc eluate. A2: O, WG phenol 
insoluble; e, Cyst 14 phenol insoluble; A, Cyst 14 fucoso eluate; <>, Cyst 14 effluent. 
than does the A2 substance. This is consistent with some qualitative differences 
between  them,  as  well  as  with  heterogeneity of the  antibody  populations 
reacting with each. 
Competition for Binding of  Labeled Blood Group Substance Between Insolu- 
bilized  Antiserum  and  Soluble  Antibody.  The  sera  used  in  the  soluble 
antibody CBA were human anti-A Chris D2 and Jos D, + D2, either unabsorbed 
or absorbed on columns of PL-Cyst 14 (A2) or PL-Hog A  (A,). The precipitating 
activities of these sera are shown in Fig. 3. The curves are typical, reaching a 
maximum and then decreasing as more antigen is added. Antibodies reacting 
with A2 substances were specifically removed (Figs.  3 b  and 3 e) by absorption 
with PL-Cyst 14 (A2). Repeated absorption with PL-Cyst 14 (A2) failed to effect 
total removal of the antibodies reacting with the A, substance. Absorption with 836  IMMUNOCHEMICAL  STUDIES  ON  BLOOD GROUPS 
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FIG.  3.  Quantitative precipitin curves  with  absorbed  and  unabsorbed human  anti-A 
serum Chris (a-c) and Jos (d-f).  (a) 100 pl serum Chris; total volume, 450  ~l.  (b) 400 ~l 
serum Chris passed through a column of PL-A2; total volume, 450 ~tl. (c) 250 ~tl serum Chris 
passed through a  column of PL-Hog A; total volume, 450  ~1.  (d) 60  ~1 serum Jos; total 
volume, 360 ~l. (e) 300 pl serum Jos passed through a column of PL-A2; total volume, 450 
~1. (f) 150 pl serum Jos passed through a column of PL-Hog A; total volume, 300 ~l. The 
antigens are: I, MSM 10% (A,); and A, WG phenol insoluble (AD. 
PL-Hog A  (A1), performed to remove only part of the ahtibodies, leaves the 
proportion of antibodies in  the  effluent reacting with A1  and A2  substance 
unchanged (Fig. 3 c and 3 f). These data agree with earlier findings (4). 
Assays  of the  ability  of the  variously  absorbed  antisera to  compete with 
insolubilized, unabsorbed Chris  D2 for the labeled HGM GalNAc eluate are 
shown in Fig. 4. The slopes of the inhibition lines measure the ability of the 
soluble antibodies to compete with the insolubilized antiserum for A determi- 
nants.  Soluble antibodies with higher affinity can compete more effectively 
than antibodies of lower affinities; the slope of the inhibition line is directly 
proportional to  relative  affinity.  Figs.  4 a  and  4b  show  the  curves  for the 
inhibition of binding with the Chris D2 and Jos D, +  D= sera from Fig. 3. They 
were absorbed at  least  twice through the indicated  PL-BGS column. The slope 
of  the  curve for  the  unabsorbed  Chris  is  108,  and  for  Jos,  78;  therefore,  Chris  has 
a higher relative  affinity  than Jos. After absorption  with PL-Cyst 14 As 
substance Chris and Jos have about the same affinities  within the experi- 
mental error  that were found for  the unabsorbed serum, i.e.,  97 for  Chris and 
73  for  Jos.  There is  little  or  no  change in  the amounts of  absorbed Chris and  Jos 
for 50% inhibition  as compared to the unabsorbed,  40 and 50 ng for Chris 
(Fig. 4  a) and 92 and 88 ng for  Jos (Fig.  4  b) respectively. 
Chris and Jos partially  absorbed on PL-Hog A, which is like  htunan A1 
substances (4, 30),  have lower binding affinities  for [~H]HGM GaINAc eluate 
than the unabsorbed sera.  This is reflected  in the lower slopes,  36 for Chris 
(Fig.  4  a),  and  31  for  Jos (Fig.  4  b).  With  both  sera,  about  five  times more AbN is 
needed to inhibit  50% binding as compared to  the unabsorbed serum. 
Figs. 4  c and d show a set  of  inhibition  curves with the samples of  Chris and 
Jos  that had been absorbed and remained from the previous study (4).  One set 
of  curves,  Chris and  Jos  absorbed with PL-McDon (A~),  were not  done for  Figs. EDWARD  C.  KISAILUS  AND  ELVIN  A.  KABAT  837 
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FIG. 4.  Competitive binding assay  with  [3H]HGM GalNAc  eluate  and  insolubilized 
human anti-A serum Chris by (a) Chris- and (h) Jos-abeorbed  (in this study) and (c) Chris- 
and (d) Jos-absorbed samples used in (4) (O), unabsorbed; (O), absorbed with PL-A2; (*), 
absorbed  with  PL-Hog  A;  (~),  absorbed  with  PL-McDon.  The  quantity giving 50% 
inhibition  of binding is indicated by an arrow and number. The number at the end of each 
line is the apparent slope (semilog plot). 
4 a  and b. The slopes with PL-McDon absorbed are similar to those of the same 
sera absorbed with PL-Hog A.  Chris absorbed on PL-Hog A  does not show as 
striking a change in relative affinity because the serum was passed through the 
column only once,  and a  smaller proportion  of the anti-A had been removed. 
The slope of the Chris absorbed on PL-Cyst 14 (A2) is greater than that of the 
unabsorbed serum,  indicating that its relative affinity is higher.  Only 16 ng of 
PL-Cyst 14 absorbed Chris inhibits 50% binding. This is threefold less than that 
with unabsorbed Chris.  Jos D~ +  D2 absorbed on PL-Cyst 14 (A2) is not shown, 
since the anti-A activity of this absorbed serum had not been determined  (4). 
However, a soluble antibody CBA was performed adding various volumes of the 
absorbed serum.  The slope of the inhibition line was 76 (data not shown), and 
thus  the  relative  affinity  is  the  same  as  that  of the  unabsorbed  Jos,  in 
agreement with the value in Fig. 4 b. 
Discussion 
It is clear that there are more A determinants on A, than on A2 glycoproteins 
or on erthrocytes  (39),  and this study firmly supports the views that there  is 
also a qualitative immunochemical difference, and that A, involves a structure 
not present in A2 soluble glycoproteins. The CBA inhibition curves with A1 and 
A2  substances  and  antibodies  or  lectin  yield  information  not  obtainable  by 838  IMMUNOCHEMICAL  STUDIES  ON  BLOOD  GROUPS 
quantitative precipitin inhibition, since slopes of the inhibition lines should be 
parallel if the differences are exclusively quantitative. 
D.  biflorus  has  a  homogeneous combining  site  specific  (23) for  the  A 
trisaccharide which both A determinants, A1 and A2, have in common. By CBA 
and quantitative precipitin assay (23) with Dolichos,  there are quantitatively 
more of these terminal groups in A1 than in A2 saliva and cyst substances, and 
by CBA, the slopes are parallel as expected (Fig. 2 a). There are also about five 
times more Dolichos-reactive sites on A1 than on A2 erythrocytes, as determined 
by electron microscopy of human erythrocytes with ferritin-conjugated  Dolichos 
(4O). 
The findings in Fig.  2 a  are of interest because they show that A~  and A2 
macromolecules which differ ll-fold in their number of reactive groups per unit 
of weight will give lines with the same slope in CBA, provided the receptor site 
(Dolichos)  is  recognizing  the  same  structure  on  each  determinant.  Thus, 
variation in the number of sites per glycoprotein molecule, e.g., in their valence 
and despite their polydispersity, does not significantly affect the slope. 
With  anti-A,  which  is  a  heterogenous population of antibody molecules, 
however, the individual A1 substances varied about twofold in number of their 
determinants per unit of weight. However, A2 substances from two individuals, 
WG phenol insoluble from human saliva, and Cyst 14 phenol insoluble (A~), fell 
on the  same curve.  Cyst  14  phenol insoluble  (A2) was  separated  on Lotus- 
Sepharose into two portions, the nonabserbed effluent (about one-third) and 
the absorbed fraction elutable by fucose (two-thirds). The finding (30) that the 
fucose eluate was about as potent in precipitating anti-A while the effluent had 
only 54% of the precipitating activity is in good agreement with experimental 
values in Fig. 2 b, the effluent having ---40% of  the activity of  the original Cyst 14 
phenol insoluble (A2) or the fucose eluate. 
The slopes of the A~ and A2 inhibition curves with inselubilized anti-A serum 
are not parallel (Fig. 2 b), indicating a qualitative difference. This is supported 
by the quantitative precipitin finding that although both A~ and A2 substances 
reach equivalence in the same region and decrease as more antigen is added, 
the amount of AbN precipitated at equivalence by A2 substance is less than that 
precipitated by A1 substance (4). If the difference were only quantitative, one 
would expect to reach the same maximum with A2 substance and the inhibition 
lines to be parallel in CBA. Thus, there is a  proportion of anti-A antibodies, 
anti-A~, which do not precipitate with A2 substance and do bind in CBA. The 
specificity of these antibodies could be for the A-specific trisaccharide linked 
81--3  to DGlcNAc to give a  type 1 determinant. Such antibodies must have 
sites large enough to accommodate the whole determinant. The antibodies from 
Chris anti-A have been purified (34) according to size of the combining site by 
elution from PL-Hog A with DGalNAc followed by the ARL 0.52 pentasaccharide 
with the structure (5, 7) 
LFucal 
2 
DGaINAcal--*3DGaI~I--*4DGIcNAc~I--*6R. 
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centrifugation. The IgG and IgM from the GalNAc and ARL 0.52 eluates were 
similar in precipitating A1 substance, whereas a smaller proportion of both IgG 
eluates was precipitated by A2 substance. The IgM eluates were not tested. A2 
substance precipitated a larger proportion of antibodies from the IgG GalNAc 
eluate than from the IgG ARL 0.52 eluate (4). The GalNAc eluate would be 
expected to have more sites specific for the smaller trisaccharide structure 
LFucal 
2 
DGalNAca--~3DGal 
which A1 and A~ share, whereas the ARL 0.52 eluate would have more sites of 
larger size.  The suggestion that a  portion of the IgG anti-A is A1  specific  is 
contrary to the assumption of the quantitative theory that IgG anti-A aggluti- 
nates both A~ and A2 cells (3). 
Only a small proportion of the absorbed Chris (31%) is eluted with AR~. 0.52, 
and the slope difference in CBA is presumably measuring this antibody. The 
absorption experiments are consistent with this. Removal of A2-reactive anti- 
bodies by absorption with PL-Cyst 14 (A2)  leaves an effluent which is A1 specific 
(4), and has the same relative affinity as the unabsorbed serum (Figs.  4 a and 
b), or even higher (Fig. 4 c). Removal of a proportion of high-affinity antibodies 
by absorption on PL-Hog A or PL-McDon (A~)  yields effluents of lower affinity. 
The  AR~. 0.52 eluate from Chris  was  found to  contain  18%  IgM  anti-A, 
whereas that from Jos had no IgM anti-A (34). This is in accord with the finding 
that after absorption with PL-Cyst 14 (A2), Chris had enhanced its capacity to 
inhibit per unit of weight as compared to the unabsorbed serum; with Jos, the 
PL-Cyst 14  (A2) absorbed and the unabsorbed serum had the same binding 
affinities. 
The  ability  to  prepare  anti-Al-specific antibodies  by  absorption  with  A~ 
erythrocytes (3)  or insolubilized A2  glycoprotein from ovarian cyst fluid  (4) 
casts doubt on findings that only type 2 chains are present on the glycoprotein 
ABH determinants of erythrocytes. Moreover, there are two important inde- 
pendent immunological observations which strongly support the association of 
A~ determinants with the type 1 chain and A2 determinants with the type 2 
chain. One of these is the discovery of an antibody which reacted only with 
OILe(a -b+) erythrocytes (41). Since this antibody cannot react with the type 1 
A determinant on A~ erythrocytes  in which a DGalNAc would be substituted on 
the DGal of the HLe  b determinant, but can react with A2 or O  erythrocytes 
which would lack  the  type  1 A  determinant, type  1 A  chains that  are  A~ 
determinants must be present on the erythrocytes. The second is the demonstra- 
tion of an antibody specific for an A~Le  b determinant (42-44) which reacted only 
with A~Le  b erythrocytes  but not with A2Le  b, OLe  b, or A~Le  a erythrocytes. Thus, 
the  combining site  of this  antibody  requires  a  type  1  A  chain for the  A~ 
specificity on erythrocytes. 
Mohn et al. (45) have recently demonstrated a qualitative difference between 
A1 and A2 erythrocytes  by gel diffusion using erythrocyte  stromata and antisera 
to human A1 and A~_ saliva produced in rabbits which secreted an A-like sub- 
stance in their saliva. 840  IMMUNOCHEMICAL  STUDIES  ON  BLOOD  GROUPS 
Hakomori et al.  (46) demonstrated that two of four A active glycolipids isolated 
from A1 erythrocytes  were absent from A~ erythrocytes  but all four were built of 
type 2 chains, one linked ill-*3 and the other/31--,6 to the same DGal. One of  the 
four glycolipids has an additional branch of undetermined structure. These A 
glycolipids,  excluding the undetermined branch, all involve type 2 chains and 
would not account for our findings, nor for those of Mohn et al.  (45). 
Summary 
Competitive binding assays using 3H-labeled  blood group A  substance and 
insolubilized  Dolichos  biflorus  lectin  or  human  anti-A  were  carried  out, 
measuring competition by blood group A~ and A2 glycoproteins, and by unab- 
sorbed anti-A sera, and with these sera absorbed with the A~ and A2 glycopro- 
teins. With Dolichos  lectin specific for 
~l~ucal 
$ 
2 
DGalNAc  al--->3vGal---~, 
A~ substances had about 11 times as many determinants as did A2 substances, 
but the slopes of the lines in the competitive binding assays were the same. 
With insolubilized anti-A, A2 substances gave lines of lower slopes.  Although 
individual A1 populations varied in the amounts giving 50% inhibition in the 
assays, as did A2 substances, the slopes of the lines for the A1 substances were 
the same and always higher than the slopes of the lines for the A2 substances. 
Competitive binding assays with unabsorbed anti-A sera and with these sera 
absorbed with insoluble pelyleucyl A~ and A2 substances showed that partial 
absorption  of polyleucyl A~  substances left antibodies of lower slope  in  the 
supernate,  whereas absorption  with  polyleucyl A~  substance left  antibodies 
(anti-A~) having the same or an even higher slope than the unabsorbed sera. 
The  findings  indicate  that  human A~  and  A2  glycoproteins differ in  their 
determinants, and that A~ specificity is determined by the type 2 chain in which 
the A trisaccharide 
LFucexl 
$ 
2 
DGalNAc al-->3 DGal- 
is linked /31--.4 to DGlcNAc, whereas the A1  specificity is determined by the 
type 1 chain in which this trisaccharide is linked ill-->3 to DGlcNAc; most of the 
determinants in the glycoproteins have a second LFuc linked al--*3 and al~4 
to the DGlcNAc of the type 2 and type 1 chains, respectively. 
Received for publication 21 November 1977. 
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